These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3298133)

  • 1. Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs.
    Welander CE
    Invest New Drugs; 1987; 5 Suppl():S47-59. PubMed ID: 3298133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferons in the treatment of multiple myeloma.
    Cooper MR; Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferons in the treatment of multiple myeloma.
    Cooper MR
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):13-20. PubMed ID: 3764441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel RJ
    Invest New Drugs; 1987; 5 Suppl():S41-6. PubMed ID: 3597002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay.
    Welander CE; Morgan TM; Homesley HD; Trotta PP; Spiegel RJ
    Int J Cancer; 1985 Jun; 35(6):721-9. PubMed ID: 4008100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
    N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa-2b-cyclophosphamide combination studies: in vitro and phase I-II clinical results.
    Durie BG; Clouse L; Braich T; Grimm M; Robertone AB
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):84-8. PubMed ID: 3764444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the clinical studies of alpha-interferon in the management of multiple myeloma.
    Cooper MR
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin.
    Von Hoff DD; Sarosy G; Brown TD; Kuhn JG; Kisner DL
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):72-7. PubMed ID: 3764442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma.
    Ozer H; Anderson JR; Peterson BA; Budman DR; Henderson ES; Bloomfield CD; Gottlieb A
    Invest New Drugs; 1987; 5 Suppl():S27-33. PubMed ID: 3298131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of interferon in the treatment of multiple myeloma.
    Costanzi JJ; Pollard RB
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):24-8. PubMed ID: 3296211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of scheduling and ascites-associated macrophages on combined antiproliferative activity of alpha-2b interferon and gamma-interferon in a clonogenic assay.
    Higashihara J; Saito T; Berens ME; Welander CE
    Cancer Chemother Pharmacol; 1988; 22(3):215-22. PubMed ID: 3136942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs.
    Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):617-9. PubMed ID: 3802026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay.
    Saito T; Berens ME; Welander CE
    Cancer Chemother Pharmacol; 1987; 19(3):233-9. PubMed ID: 3107848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
    Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
    J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
    J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Falcoff E; Schwab D; Lerminier M; Pouillart P
    Invest New Drugs; 1987; 5 Suppl():S61-3. PubMed ID: 3597003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alfa-2b in the treatment of chronic granulocytic leukemia.
    Bergsagel DE; Haas RH; Messner HA
    Invest New Drugs; 1987; 5 Suppl():S9-17. PubMed ID: 3298136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
    Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
    Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma.
    Chisesi T; Capnist G; Vespignani M; Cetto G
    Invest New Drugs; 1987; 5 Suppl():S35-40. PubMed ID: 3298132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.